Live from ASCO
So lots of exciting news coming out of the ASCO meetings - especially around Melanoma. While it sucks to have it, it's a much better time to have now vs. 5 years ago! Hoping everyday with these new clinical trials and research we get closer to a cure! or at least making Melanoma a manageable disease vs. a death sentence.
This morning when I picked up the ASCO daily news front page headline is: Investigational Immunotherapies Offer Bring Prospects in Advanced Melanoma! Of course with the FDA approval of Ipilimumab a few years ago (aka Yervoy), it seems that more and more focus is going towards developing these types of drugs vs. the standard type Chemos! You wouldn't believe how many different exhibitors are here with that as their focus!
I think you are all seeing the numbers, but in case you haven't here they are:
The interim overall response rate for lambrolizumab was 38%, according to investigators, who reported interim data on 135 patients with advanced melanoma. The highest response rate was an impressive 52% in the arm receiving 10 mg/kg every two weeks, the highest dose in the study. Ten percent of the patients in that arm achieved a complete response, with response duration ranging from 28 days to 8 months. Four out of five patients who responded stayed on treatment. And after a median follow-up time of 11 months, the median rate of response has not yet been reached in the study.